Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Long-Term Clinical Results of Ab-Interno Trabeculotomy in Glaucoma Management

21. august 2026 oppdatert av: Raoul Verma-Führing, Wuerzburg University Hospital

Glaucoma is one of the leading causes of irreversible vision loss worldwide. Elevated intraocular pressure (IOP) is the most important risk factor for the development and progression of the disease.

Ab-interno trabeculotomy (AIT) using the Trabectome system is a minimally invasive glaucoma surgery (MIGS) that reduces aqueous humor outflow resistance by ablating the trabecular meshwork and the inner wall of Schlemm's canal, thereby lowering intraocular pressure.

Previous studies have demonstrated good short-term efficacy of this procedure. However, robust long-term data spanning several years remain scarce.

The aim of this study is to evaluate the long-term outcomes of AIT in glaucoma patients who underwent surgery between 2019 and 2021 at the Department of Ophthalmology, University Hospital Würzburg. Patients are invited for a single study visit at which intraocular pressure, visual acuity, anterior chamber angle by gonioscopy, and optic nerve structure by optical coherence tomography (OCT) are assessed. The collected data are compared with pre-operative baseline values obtained from medical records.

The results are intended to improve the assessment of long-term surgical success and to optimize patient selection for this procedure in the future.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

Glaucoma is a progressive optic neuropathy in which elevated intraocular pressure (IOP) represents the primary modifiable risk factor. Ab-interno trabeculotomy (AIT) with the Trabectome is a minimally invasive glaucoma surgery (MIGS) that reduces IOP by ablating the trabecular meshwork and inner wall of Schlemm's canal, thereby improving aqueous humor outflow.

Previous studies have demonstrated favorable short-term IOP reduction and a good safety profile. However, robust long-term data evaluating sustained surgical success, disease progression, and the need for additional interventions over multiple years are currently lacking.

This single-center, observational study with a retrospective pre-operative baseline and a prospective cross-sectional follow-up visit addresses this knowledge gap. Patients who underwent AIT at the Department of Ophthalmology, University Hospital Würzburg, are contacted and invited for a single study visit of approximately 30 minutes.

At this visit, the following assessments are performed:

  • Medical history review since the time of surgery
  • Visual acuity assessment
  • Goldmann applanation tonometry (IOP measurement)
  • Slit-lamp biomicroscopy including gonioscopy for the anterior chamber angle
  • Optical coherence tomography (OCT) of the optic nerve head and retinal nerve fiber layer (RNFL)

All examinations are non-invasive, painless, and consistent with routine ophthalmic care. No additional follow-up visits are required beyond this single study contact.

Pre-operative data, including baseline IOP, glaucoma diagnosis, medication use, and surgical details are obtained from existing medical records. These are compared with findings at the study visit to evaluate long-term treatment success.

The study is initiated and funded by the Department of Ophthalmology, University Hospital Würzburg. No external funding or industry sponsorship is involved. The study has been approved by the responsible Ethics Committee with no objections raised.

Approximately 180 participants are planned for enrollment. Data are pseudonymized and stored on password-protected servers. No data transfer to third parties or outside the European Union is performed. Data will be deleted no later than 10 years after study completion.

Studietype

Observasjonsmessig

Registrering (Antatt)

200

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Raoul Verma-Führing, Dr.
  • Telefonnummer: +49 931 20120458
  • E-post: augenklinik@ukw.de

Studer Kontakt Backup

Studiesteder

  • Tyskland
    • Bavaria
      • Würzburg, Bavaria, Tyskland, 97080
        • Rekruttering
        • University Hospital Würzburg
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Patients with glaucoma who underwent ab-interno trabeculotomy (AIT) using the Trabectome device at the Department of Ophthalmology, University Hospital Würzburg, between 2019 and 2021. Patients were identified retrospectively through surgical records and invited for a single prospective follow-up visit in order of longest time elapsed since surgery, prioritizing those operated earliest within the inclusion period.

Beskrivelse

Inclusion Criteria:

  • Diagnosis of glaucoma
  • Previous ab-interno trabeculotomy (AIT) using the Trabectome device performed at the Department of Ophthalmology, University Hospital Würzburg
  • Surgery performed between 2019 and 2021
  • Ability to provide written informed consent
  • Age ≥ 18 years at time of surgery

Exclusion Criteria:

  • Inability to attend the study visit
  • Withdrawal of informed consent
  • Insufficient medical records for pre-operative baseline data retrieval

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
AIT Cohort
Tha AIT cohort consists of glaucoma patients who previously underwent ab-interno trabeculotomy (AIT) using the Trabectome device at the Department of Ophthalmology, University Hospital Würzburg. Participants are invited for a single follow-up visit to assess long-term intraocular pressure control, visual acuity, optic nerve status (OCT), and visual field outcomes compared to pre-operative baseline data obtained from medical records.
Fremgangsmåte: Ab-interno trabeculotomy
Ab-interno trabeculotomy (AIT) is a minimally invasive glaucoma surgery (MIGS) performed using the Trabectome device. The procedure ablates the trabecular meshwork and the inner wall of Schlemm's canal via an ab-interno approach, thereby reducing resistance to aqueous humor outflow and lowering intraocular pressure. The surgery is performed under local or general anesthesia and can be combined with cataract surgery. In this observational study, the intervention was performed prior to study enrollment; no surgical intervention is performed as part of the study itself.
Andre navn:
  • AIT
  • Trabectome

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Intraocular Pressure (IOP) from Pre-operative Baseline to Follow-up
Tidsramme: From pre-operative baseline to single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Mean intraocular pressure (mmHg) measured by Goldmann applanation tonometry at the study visit, compared to pre-operative baseline IOP obtained from medical records. Surgical success is defined as IOP reduction of ≥20% from baseline and/or IOP ≤18 mmHg, with or without anti-glaucomatous medication.
From pre-operative baseline to single follow-up visit (minimum 4 years, up to 10 years post-surgery)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Number of Intraocular Pressure-Lowering Medications from Pre-operative Baseline to Follow-up
Tidsramme: From pre-operative baseline to single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Total number of topical and systemic anti-glaucomatous medications used by the patient at the time of the study visit, compared to the number documented in medical records prior to surgery. Reduction in medication burden is considered an additional indicator of surgical success.
From pre-operative baseline to single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Visual Acuity at Follow-up
Tidsramme: At single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Visual acuity assessed using standardized visual acuity charts at the study visit. Results are recorded in decimal notation and converted to logMAR for analysis. Pre-operative VA is obtained from medical records for comparison.
At single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Peripapillary Retinal Nerve Fiber Layer (RNFL) Thickness as Measured by Optical Coherence Tomography (OCT)
Tidsramme: At single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Peripapillary RNFL thickness (µm) assessed by spectral- domain optical coherence tomography (SD-OCT) at the study visit. Global and sectoral RNFL values are recorded. Results are compared to pre-operative OCT data from medical records where available, to evaluate structural progression of glaucomatous optic neuropathy.
At single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Rate of Surgical Failure Requiring Additional IOP-Lowering Intervention After Ab-Interno Trabeculotomy
Tidsramme: From date of surgery to single follow-up visit (minimum 4 years, up to 10 years post-surgery)
Proportion of patients who required additional surgical or laser intervention (e.g., trabeculectomy, tube shunt implantation, selective laser trabeculoplasty) due to insufficient IOP control following AIT. Data obtained retrospectively from medical records. Surgical failure is defined as the need for re-intervention at any time point after the primary procedure.
From date of surgery to single follow-up visit (minimum 4 years, up to 10 years post-surgery)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Wuerzburg University Hospital

Etterforskere

  • Hovedetterforsker: Raoul Verma-Führing, Dr., Wuerzburg University Hospital

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

3. desember 2025

Primær fullføring (Antatt)

1. november 2026

Studiet fullført (Antatt)

1. februar 2027

Datoer for studieregistrering

Først innsendt

18. august 2026

Først innsendt som oppfylte QC-kriteriene

18. august 2026

Først lagt ut (Faktiske)

24. august 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

25. august 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. august 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Nøkkelord

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • 2025-330-dvha

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere